64 related articles for article (PubMed ID: 729476)
21. [Combined chemotherapy and anti-oestrogen administration for metastasising breast carcinoma: randomised study comparing AVC and AVC plus tamoxifen (author's transl)].
Link H; Rückle H; Waller HD; Wilms K
Dtsch Med Wochenschr; 1981 Sep; 106(39):1260-2. PubMed ID: 6896301
[TBL] [Abstract][Full Text] [Related]
22. [Operable carcinoma of the breast. Prognostic value of estradiol receptors. Preliminary report (author's transl)].
Cheix F; Biron A; Bailly C; Mayer M; Pommatau E; Saez S
Nouv Presse Med; 1980 Mar; 9(13):933-5. PubMed ID: 7360626
[TBL] [Abstract][Full Text] [Related]
23. [Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)].
Mayr AC; Senn HJ; Gallmeier WM; Bruntsch U; Becher R; Drings P; Fritze D; Kaufmann M; Queisser W; Kempgens U
Dtsch Med Wochenschr; 1979 Dec; 104(49):1739-43. PubMed ID: 510206
[TBL] [Abstract][Full Text] [Related]
24. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
[TBL] [Abstract][Full Text] [Related]
25. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
Mahtani RL; Stein A; Vogel CL
Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
[TBL] [Abstract][Full Text] [Related]
26. [Demonstration of the effect of estrogen and progesterone receptors on survival in breast cancer without cytostatic and hormonal treatment in a small set of patients].
Hochmann J
Klin Onkol; 2010; 23(1):25-33. PubMed ID: 20192071
[TBL] [Abstract][Full Text] [Related]
27. Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
Panagos GE
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S17-21. PubMed ID: 9071335
[TBL] [Abstract][Full Text] [Related]
28. [Androgen receptors in primary breast carcinoma. Relation to prognostic factors in comparison with estrogen and progesterone receptors].
Reiner G; Jakesz R; Kolb R; Kühnl-Brady K; Reiner A; Schemper M; Spona J
Dtsch Med Wochenschr; 1988 Jun; 113(22):892-7. PubMed ID: 3371221
[TBL] [Abstract][Full Text] [Related]
29. The effect of ethynyloestradiol and medroxyprogesterone acetate on the in vivo uptake and metabolism of 3H-oestradiol by breast tumour tissue in postmenopausal women.
Reed MJ; Beranek PA; Bonney RC; Ghilchik MW; James VH
Anticancer Res; 1987; 7(6):1265-9. PubMed ID: 2831795
[TBL] [Abstract][Full Text] [Related]
30. [High-dosed gestagen therapy of the metastatic mammary carcinoma (author's transl)].
Firusian N; Becher R
Strahlentherapie; 1981 Dec; 157(12):808-12. PubMed ID: 7330909
[TBL] [Abstract][Full Text] [Related]
31. Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study.
Fabian CJ; Kimler BF; McKittrick R; Park CH; Lin F; Krishnan L; Jewell WR; Osborne CK; Martino S; Hutchins LF
Cancer Res; 1994 Oct; 54(20):5357-62. PubMed ID: 7923165
[TBL] [Abstract][Full Text] [Related]
32. Sequential cyclic combined hormonal therapy for metastatic breast cancer.
Hortobagyi GN; Hug V; Buzdar AU; Kau SW; Holmes FA; Fritsche HA
Cancer; 1989 Sep; 64(5):1002-6. PubMed ID: 2527085
[TBL] [Abstract][Full Text] [Related]
33. [On the value of a combination of estrogens and alkylating substances in the treatment of a metastasizing breast carcinoma of the female].
Nowakowski H; Ruhstrat K
Dtsch Med Wochenschr; 1966 Oct; 91(40):1775-9. PubMed ID: 5922726
[No Abstract] [Full Text] [Related]
34. A multidisciplined approach for the treatment of metastatic carcinoma of the breast.
Oberfield RA; Nesto R; Cady B; Pazianos AG; Salzman FA
Med Clin North Am; 1975 Mar; 59(2):425-30. PubMed ID: 46945
[TBL] [Abstract][Full Text] [Related]
35. Rebound response after estrogen therapy for metastatic breast cancer.
Nesto RW; Cady B; Oberfield RA; Pazianos AG; Salzman FA
Cancer; 1976 Oct; 38(4):1834-7. PubMed ID: 991097
[TBL] [Abstract][Full Text] [Related]
36. Hormonal therapy of breast cancer with special reference to Masteril therapy.
Bennett MB; Helman P; Palmer P
S Afr Med J; 1975 Nov; 49(49):2036-40. PubMed ID: 1242823
[TBL] [Abstract][Full Text] [Related]
37. [Hyperlipoproteinaemia during additional methenolone administration in the treatment of metastasizing carcinoma of the breast].
Garbrecht M; Lehmann U; O'Brien S; Stolzenbach G; Müllerleile U
Dtsch Med Wochenschr; 1981 Mar; 106(13):400-3. PubMed ID: 7215163
[TBL] [Abstract][Full Text] [Related]
38. Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study.
Heuson JC; Engelsman E; Blonk-Van Der Wijst J; Maass H; Drochmans A; Michel J; Nowakowski H; Gorins A
Br Med J; 1975 Jun; 2(5973):711-3. PubMed ID: 1095121
[TBL] [Abstract][Full Text] [Related]
39. [Estrogen therapy of advanced breast cancer].
Massidda B; Mascia V; Broccia G; Pasqualucci S; Deplano W; Desogus A; Luxi G; Pellegrini A
Minerva Med; 1977 Jul; 68(36):2509-16. PubMed ID: 887230
[TBL] [Abstract][Full Text] [Related]
40. The value of combined therapy with estrogens and alkylating agents in metastasizing carcinoma of the breast.
Nowakowski H; Ruhstrat K
Ger Med Mon; 1966 Dec; 11(12):493-7. PubMed ID: 5977990
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
